Compare MCFT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | VYGR |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.1M | 203.6M |
| IPO Year | 2015 | 2015 |
| Metric | MCFT | VYGR |
|---|---|---|
| Price | $22.98 | $3.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $24.25 | $16.50 |
| AVG Volume (30 Days) | 147.2K | ★ 568.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $284,203,000.00 | $10,135,000.00 |
| Revenue This Year | $9.18 | $34.04 |
| Revenue Next Year | $8.23 | $7.92 |
| P/E Ratio | $68.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.19 | $2.83 |
| 52 Week High | $28.44 | $5.55 |
| Indicator | MCFT | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 43.51 |
| Support Level | $21.90 | $3.31 |
| Resistance Level | $23.08 | $4.29 |
| Average True Range (ATR) | 0.77 | 0.20 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 35.22 | 30.77 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.